Floatz logo

PROPADERM FORTE

Stage IV Adult Diffuse Small Cleaved Cell Lymphoma

Fred Hutchinson Cancer CenterSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Stage IV Adult Diffuse Small Cleaved Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
University of Chicago
Phase 2BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
University of Chicago
Phase 2BB
TACROLIMUS
National Cancer Institute (NCI)
Phase 2BB
Fludarabine
Case Comprehensive Cancer Center
Phase 2BB
Irinotecan
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

PROPADERM FORTE is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
67 / 100
View asset →
graft versus host diseaseDormant
BB
Indicative ·
64 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →